ADI (arginine deiminase), an enzyme that hydrolyses arginine, has been reported as an anti-angiogenesis agent. However, its molecular mechanism is unclear. We have demonstrated for the first time that ADI modulates the angiogenic activity of endothelial tip cells. By arginine depletion, ADI disturbs actin filament in endothelial tip cells, causing disordered migratory direction and decreased migration ability. Furthermore, ADI induces excessive synthesis of ROS (reactive oxygen species), and activates caspase 8-, but not caspase 9-, dependent apoptosis in endothelial cells. These findings provide a novel mechanism by which ADI inhibits tumour angiogenesis through modulating endothelial tip cells.
Introduction
ADI (arginine deiminase) (EC 3.5.3.6) is an enzyme that hydrolyses arginine irreversibly [1] . ADI converts plasma arginine into citrulline, a metabolite which is taken up and converted back into arginine by normal cells and tissues except melanoma or hepatocellular carcinomas [2, 3] . Depletion of arginine by ADI was reported to inhibit the survival of those arginine-dependent tumour cells [4] . Moreover, ADI was reported to inhibit angiogenesis by depletion of arginine and arrest the endothelial cell cycle [5] . However, the exact mechanism of ADI in inhibiting tumour angiogenesis is still unclear.
ADI has been reported to regulate the activities of inducible and endothelial nitric oxide synthase (iNOS and eNOS respectively) in endothelial cells [6] . eNOS, an endothelial cell enzyme that catalyses the production of NO (nitric oxide) from L-arginine, plays a vital role in regulating vascular function [7] . NO has been identified as a key mediator in angiogenesis [8] . Under stress conditions, eNOS transforms from a protective enzyme to a contributor that is prone to secreting ROS (reactive oxygen species) through eNOS uncoupling [9] . In fact, eNOS-dependent superoxide formation might play an important role in the pathology of conditions such as angiogenesis. Importantly, Ushio-Fukai and Alexander [10] have demonstrated that ROS, as a secondary messenger, is critical for VEGF Key words: angiogenesis, apoptosis, arginine deiminase, endothelial tip cell, reactive oxygen species. Abbreviations used: ADI, arginine deiminase; bFGF, basic fibroblast growth factor; eNOS, endothelial nitric oxide synthase; F-actin, filamentous actin; HMEC, human microvascular endothelial cell; l-NAME, N G -nitro-l-arginine methyl ester; Mn(III)TMPyP, tetra-Nmethylpyridylporphyrinatomanganese(III); ROS, reactive oxygen species; SOD, superoxide dismutase; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; Z-IETD-FMK, benzyloxycarbonyl-Ile-GluThr-Asp-fluoromethylketone. 1 To whom correspondence should be addressed (email yluo@tsinghua.edu.cn).
(vascular endothelial growth factor) signalling [10] . Low concentrations of ROS can trigger the activation of certain signalling pathways to modulate angiogenesis [10] . On the other hand, large amounts of ROS are considered to be toxic products that cause cell death or apoptosis [11] .
Angiogenesis, the growth of new capillary blood vessels, is critical for development, reproduction, tissue repair and many pathological conditions such as cancer. Under hypoxic conditions, tumour cells secrete growth factors, such as VEGF. In response to VEGF, quiescent endothelial cells become activated and initiate the angiogenic sprouting. The tips of these sprouts are formed by specialized endothelial tip cells. Tip cells are migratory endothelial cells which lead the direction of new sprouts by extending numerous filopodia to sense the local microenvironment [12] . As ROS are involved in regulating VEGF pathway, which is important for the activity of endothelial tip cells, we wondered whether ADI influences the activity of endothelial tip cells, leading to the inhibition of tumour angiogenesis.
In our studies, we have demonstrated that ADI modulates the angiogenic activity of endothelial tip cells stimulated by tumour cells. Moreover, we have elucidated the molecular mechanism that ADI treatment induces caspase 8-dependent apoptosis of endothelial cells through excessive synthesis of ROS. Full experimental details can be found in the Supplementary Online Data at http://www.biochemsoctrans. org/bst/039/bst0391376add.htm. and evaluated the migration ability of HMECs upon ADI treatment. After treatment with 10 μg/ml ADI, the migration of HMECs was inhibited by ∼50% or ∼30% when co-cultured with HeLa or MCF-7 cells respectively ( Figure 1A ). In the scraping assay, HMECs were cultured with the conditioned medium of HeLa or MCF-7 cells and treated with ADI simultaneously. The recovery of scraped ADI-treated HMECs was slower than that of untreated cells ( Figure 1B) . Interestingly, after ADI treatment, the migratory direction of endothelial tip cells was significantly interrupted and disordered ( Figure 1C) . Meanwhile, the composition and distribution of F-actin (filamentous actin) among actin filaments were disturbed in ADI-treated HMECs ( Figure 1D ). Since tumour-secreted VEGF-A and bFGF (basic fibroblast growth factor) are the major regulators of endothelial tip cell migration [12] , HMECs were stimulated with either VEGF-A or bFGF, and treated with ADI. Intriguingly, ADI markedly attenuated the VEGF-A-stimulated, but not the bFGF-stimulated group ( Figure 1E ). Simultaneously, ADI treatment down-regulated the expression level of VEGFR-2 (VEGF receptor 2) ( Figure 1F ). These results demonstrate that ADI modulates the activity of endothelial tip cells, which contributes to the inhibition of tumour angiogenesis.
ADI causes apoptosis of endothelial cell via the caspase 8 pathway
ADI is an enzyme which hydrolyses arginine irreversibly [1] . To verify whether the inhibitory effect of ADI on endothelial tip cells is caused by the depletion of arginine, we constructed an ADI inactive mutant H268F, which was reported to lose enzymatic activity in the hydrolysis of arginine [14] . As expected, the ADI-inactive mutant H268F could not inhibit the migration of HMECs (Figure 2A ). Consistently, H268F did not influence endothelial tip cell activity in the scrape assay ( Figure 2B ). Thus we concluded that ADI inhibits the activity of endothelial tip cells by the depletion of arginine.
Since arginine is crucial for the cell cycle, and the depletion of arginine causes cell apoptosis [5] , we suspected that ADI also induces apoptosis of endothelial tip cells. After being treated with ADI for 24 h, HMECs were examined using an annexin V/PI (propidium iodide) assay. Compared with untreated cells, more HMECs were labelled with annexin V in the ADI-treated group ( Figure 2C ), suggesting that ADI treatment induces apoptosis of endothelial cells. To investigate the mechanism involved in ADI-induced apoptosis, the expression of apoptosis-related proteins in HMECs was detected by Western blotting after ADI treatment. ADI treatment activated caspase 8. However, the other critical caspase, caspase 9, was not significantly modulated by ADI treatment ( Figure 2D ). Flow cytometry results showed that the caspase 8 inhibitor [Z-IETD-FMK (benzyloxycarbonylIle-Glu-Thr-Asp-fluoromethylketone)] could completely rescue the HMECs apoptosis induced by ADI treatment ( Figure 2C ). These results demonstrate that ADI induced the apoptosis of endothelial cells in a caspase 8-dependent pathway. 
ADI promotes ROS production in endothelial cells and regulates the phosphorylation of eNOS
Since ADI can notably regulate the activity of eNOS via the depletion of arginine in endothelial cells [6] , and both of the eNOS products (NO and ROS) are regulators of angiogenesis [8, 10] , we wondered whether NO and ROS could be involved in the ADI-induced apoptosis of HMECs. As expected, ADI inhibited the release of NO from HMECs ( Figure 3A ). L-NAME (N G -nitro-L-arginine methyl ester), an eNOS inhibitor, reduced the production of NO by 26%. However, the combined treatment of ADI and L-NAME did not show a synergistic inhibition on NO release ( Figure 3A) . Moreover, ADI treatment significantly increased the release of ROS from HMECs by 64% ( Figure 3A) . The combined treatment of ADI and L-NAME showed a 54% increase in ROS production ( Figure 3A) . Thus the depletion of arginine by ADI caused excessive synthesis of ROS and slightly decreased production of NO in endothelial cells.
Increased levels of ROS may regulate the activation of eNOS [15] , which is the synthesis machine of NO and ROS in endothelial cells. Activation of eNOS mainly depends on its variant phosphorylation at different serine and tyrosine residues [16] . The effect of ADI on the activation of eNOS was determined by Western blotting. ADI did not modulate the expression of eNOS in HMECs ( Figure 3B ). However, ADI treatment could remarkably enhance the phosphorylation of eNOS at its serine and tyrosine residues, which was detected by specific polyclonal antibodies against the phosphorylation of serine or tyrosine residues. Mn(III)TMPyP [tetra-N-methylpyridylporphyrinatomanganese(III)], a manganese porphyrin which acts as a SOD (superoxide dismutase) mimetic and peroxynitrite decomposition catalyst, could significantly attenuate the phosphorylation of eNOS (Figure 3B) . Taken together, these results illustrate that ADI can induce excessive ROS release from endothelial cells and modulate the activity of eNOS.
Excessive ROS production induced by ADI modulates the activity of endothelial tip cells
High concentrations of ROS can cause necrosis or apoptosis [11] . To demonstrate that excessively released ROS contributes to ADI-induced apoptosis and inhibition of endothelial tip cell activity, we employed a TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nickend labelling) assay to analyse the apoptotic HMECs. After ADI treatment, the number of endothelial cells producing excessive ROS was significantly increased, resulting in the DNA fragmentation and apoptosis ( Figure 3C ). As expected, Mn(III)TMPyP dramatically inhibited the synthesis of ROS induced by ADI and attenuated ADI-induced HMEC apoptosis ( Figure 3C) . Similarly, flow cytometry results showed that Mn(III)TMPyP could rescue ADI-induced HMEC apoptosis ( Figure 3D ).
We expected that the depletion of ROS by Mn(III)TMPyP treatment could prevent the inhibitory effect of ADI on endothelial tip cells. In the scrape assay, cells were co-treated with ADI and Mn(III)TMPyP. Mn(III)TMPyP blocked the modulation effect of ADI on the distribution and organization of F-actin among the actin filaments ( Figure 3E ). Therefore our results provide clear evidence that ADI modulates the cytoskeleton and induces apoptosis of endothelial tip cells through excessive ROS expression.
ADI inhibits tumour cell-induced angiogenesis
ADI is an enzyme which degrades arginine irreversibly [1] . Shen and colleagues first demonstrated that ADI was able to inhibit angiogenesis of HUVECs (human umbilical vein endothelial cells) in vitro by the depletion of arginine and the arrest of the endothelial cell cycle [17] . Park et al. [4] also reported the anti-angiogenic activity of ADI in vivo is primarily due to arginine depletion. However, the exact antiangiogenesis mechanism of ADI is still unclear.
Consistent with the results observed by Schweigerer and colleagues [5] , in our study, we also found that ADI inhibits angiogenic activities of HMECs stimulated by tumour cells. Moreover, we elucidated that depletion of arginine by ADI causes excessive ROS production, leading to activated caspase 8-dependent apoptosis of endothelial cell. Thus our findings investigate thoroughly the mechanism of the anti-angiogenic function of ADI.
ADI modulates angiogenic activities of endothelial tip cell
Blood vessel expands in a two-step process that begins with vessel sprouting and is followed by vessel anastomosis [18] . Vessel sprouting is induced by gradients of VEGF, which stimulates tip cell protrusion. Endothelial tip cell use filopodia to sense the VEGF gradient, attach matrix and migrate [19] . We observed that ADI disturbed the composition and distribution of F-actin among actin filaments in endothelial tip cells. Subsequently, the migratory directions of endothelial tip cells were significantly interrupted. Simultaneously, the expression of the VEGFR Flk-1/KDR (kinase insert domaincontaining receptor) (VEGFR-2) was attenuated by ADI. These observations efficiently contribute to desensitizing the responses of endothelial tip cells to stimulation by VEGF and tumour cells on migration.
How ADI modulates endothelial tip cell filopodia is of interest. Arginine is the main source of NO synthesized by endothelial cells. The deficiency of arginine can result in the inhibition of NO release. The function of NO in angiogenesis was reported to be involved in cytokine pathways such as VEGF [20] . Inhibition of NO release induced by ADI may also contribute to this process. However, the exact mechanism remains to be explored.
ADI-induced excessive ROS production activates caspase 8-dependent apoptosis of endothelial cells
eNOS is prone to secreting ROS through eNOS uncoupling [9] . In fact, eNOS-dependent superoxide formation is likely to play an important role in pathological angiogenesis [10] . Simon et al. [21] reported that oxidative stress induces the apoptosis of various mammalian cells, in which different apoptotic signalling pathways was involved. In our studies, owing to the depletion of extracellular arginine by ADI, HMECs produced excessive ROS and subsequently underwent caspase 8-dependent apoptosis after ADI treatment. Mn(III)TMPyP, as a SOD mimetic, significantly attenuates the production of ROS in HMECs and also prevents the ADI-induced apoptosis of HMECs. We concluded that ROS plays a key role in inducing the apoptotic process and regulating the angiogenic process of endothelial tip cells after ADI treatment.
Schweigerer and co-workers reported that ADI inhibits cell proliferation by arresting the cell cycle and inducing apoptosis [5] . Kim et al. [22] elucidated that ADI induces a late caspase-independent cell death in prostate cancer cells. Interestingly, we found that ADI-induced HMEC apoptosis could be executed via the significant activation of caspase 8, whereas ADI treatment did not induce the remarkable activation of caspase 9. These observations indicate that ADI triggers different apoptotic pathways on tumour cells and endothelial cells. We propose that excessive ROS production by ADI treatment could result in the activation of caspase 8, followed by endothelial cell apoptosis.
ADI treatment regulates the phosphorylation of eNOS
Although ADI can regulate the production of NO and ROS, the expression level of eNOS is not affected significantly. Alternatively, after ADI treatment, eNOS can be phosphorylated, which could regulate its activity and localization in endothelial cells as reported by Fleming and Busse [16] . eNOS can be phosphorylated on serine, threonine and tyrosine residues, which plays a potential role in regulating eNOS activity [16] . Phosphorylation at Ser 1177 has been linked with an increase in NO synthesis activity of eNOS [23] . Phosphorylation at Ser 114 induces a functional uncoupling of eNOS, resulting in increased release of superoxide [16] , which was also observed in our work that ADI activates ROS synthesis. In our study, NO was not down-regulated by ADI as dramatically as we suspected. This may be due to the Ser 1177 phosphorylation, which rescues the deficiency of NO. Simultaneously, we also found that Mn(III)TMPyP inhibits the phosphorylation of eNOS at serine and tyrosine residues, which suggests that ROS is the key regulator during ADI-induced eNOS phosphorylation.
Besides serine residues, tyrosine sites of eNOS can also be phosphorylated. However, the tyrosine phosphorylation of eNOS could not affect eNOS activity directly, but more probably determine the docking of associated proteins [16] . Using the specific antibodies against phosphorylated tyrosine residues, we indeed observed the significant change in tyrosine phosphorylation of eNOS after ADI treatment.
In our studies, we have demonstrated for the first time that ADI modulates angiogenic activity of endothelial tip cells. Moreover, we have elucidated the molecular mechanism that ADI executes its functions through arginine depletion, inducing excessive ROS expression from endothelial cells, and activating caspase 8-dependent apoptosis. This finding provides a novel insight into mechanisms of ADI-induced endothelial tip cells modulation and angiogenesis inhibition. 
SUPPLEMENTARY ONLINE

Cell culture
HMECs, MCF-7 (human breast adenocarcinoma cell line) cells and HeLa (human epithelial carcinoma cell line) cells (purchased from A.T.C.C., Manassas, VA, U.S.A.) were maintained at 37
• C, 5% CO 2 in DMEM (Dulbecco's modified Eagle's medium) (Invitrogen) supplemented with 10% (v/v) FBS (fetal bovine serum) (Hyclone), 100 μg/ml streptomycin and 100 units/ml penicillin.
Cell migration
The motility of HMECs was measured using a transwell migration assay with millicells (8 μm) as described previously [1] . Briefly, 3×10 4 HMECs were inoculated into the upper well of the millicells which were inserted in the 24-well plate seeded with tumour cells (MCF-7 or HeLa). After 6 h, the millicell inserts were fixed with 4% (w/v) pre-cooled PFA (paraformaldehyde)] and stained with H&E (haematoxylin and eosin). The number of cells migrated to the lower surface of the millicells was counted. The migration results were expressed as the average number of cells per optical microscopic (×200) field. Five fields were counted for each assay. Each sample was assayed four times, and the assays were repeated twice.
Scrape assay
Serum-deprived HMECs were grown on a fibronectincoated 24-well plate, and linear wounds were made gently using cell scrapers. After the detached cells were cleared completely with PBS, HMECs was cultured in tumour cell (MCF-7 or HeLa)-conditioned medium, containing 10 μg/ml ADI. The processes of wound healing were photographed. Experiments were performed in triplicate and repeated twice. 1 To whom correspondence should be addressed (email yluo@tsinghua.edu.cn).
Flow cytometry
HMECs grown to 90% confluence were serum-deprived in DMEM containing 0.2% FBS for 12 h and then treated for 24 h with 10 μg/ml ADI and PI (propidium iodide) according to the manufacturer's instructions (MEBCYTO Apoptosis Kit, MBL). The labelled HMECs were loaded on to the flow cytometer, and the apoptotic cells were collected and analysed according to the manufacturer's instructions.
TUNEL assay
HMECs were inoculated on coverslips, serum-deprived and treated for 24 h with 10 μg/ml ADI supplemented with 2% FBS. The samples were prepared as described in the kit user's manual (R&D) and analysed according to the manufacturer's instructions.
NO and ROS assays
The ROS and NO in medium were detected with ROS kit (Bio-Lab) and NO detection kit (Bio-Lab) respectively according to the manufacturer's instructions. The assays were repeated twice and each sample was assayed three times.
In the intracellular ROS assays, serum-deprived HMECs were treated for 24 h with ADI, L-NAME or Mn(III)TMPyP, or combinations thereof, supplemented with 2% FBS. Subsequently, the samples were prepared with the ROS assay kit (Applygen Technologies) and were assayed according to the manufacturer's instructions.
Immunofluorescence analysis
After being serum-deprived for 12 h, HMECs were cultured in DMEM supplemented with 2% FBS and ADI, L-NAME or Mn(III)TMPyP, or combinations thereof, for 24 h. The treated cells were washed with ice-cold PBS, fixed with 4% (w/v) PFA, permeabilized with 0.2% Triton X-100, and subsequently incubated with 1:200 (dilution) rabbit anti-actin polyclonal antibodies, followed by incubation with TRITC (tetramethylrhodamine β-isothiocyanate)-conjugated goat anti-rabbit IgG and 1:500 (dilution) FITC-phalloidin. The fields were photographed with an Olympus fluorescence microscope and CoolSnap digital camera.
Western blotting assays and immunoprecipitation
Serum-deprived HMECs were treated for 24 h with 10 μg/ml ADI supplemented with 2% FBS. The supernatant of lysed HMECs was boiled in SDS/PAGE loading buffer containing 2-mercaptoethanol for 20 min. The treated supernatants were separated by SDS/PAGE (12% gels) and analysed by Western blotting.
For immunoprecipitation, the supernatant was incubated with the polyclonal rabbit antibodies against eNOS (Santa Cruz Biotechnology) on ice for 4 h, and subsequently incubated with Protein A-agarose (Merck). The binding proteins on Protein A were extracted by SDS/PAGE loading buffer and the supernatant was loaded on to a 12% gel, followed by Western blotting. Anti-phosphoserine (Abcam) and anti-phosphothreonine (Cell Signaling Technology) antibodies were used.
Statistical analyses
Student's t test was used to calculate P values.
